DG
BBIO icon

David Goel’s BridgeBio Pharma BBIO Stock Holding History

David Goel’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-240,000
Closed -$6.08M – 11
2024
Q2 		$6.08M Buy
240,000
+70,000
+41% +$1.91M 0.05% 21
2024
Q1 		$5.26M Buy
+170,000
New +$5.78M 0.05% 22

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Goel's BBIO Position: Q3 2024 in Review

David Goel sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 240,000 shares — an estimated $6.08M sold.

David Goel first reported a position in BBIO in Q1 2024 and held it in 2 quarters. The position peaked at $6.08M in Q2 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • David Goel reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • David Goel sold 240,000 BridgeBio Pharma shares in Q3 2024, an estimated $6.08M.
  • David Goel first reported a position in BridgeBio Pharma in Q1 2024 and held it in 2 quarters.
  • David Goel's BridgeBio Pharma position peaked at $6.08M in Q2 2024.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Matrix Capital Management Company's 13F filing for Q3 2024, filed 14 Nov 2024.